Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis

Stanley Cohan1,2,3 1Providence Multiple Sclerosis Center, 2Providence Brain and Spine Institute, 3Providence Health & Services, Portland, OR, USA Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Cohan S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	daclizumab high-yield process disease-modifying therapy humanized monoclonal antibody relapsing multiple sclerosis therapeutic use Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a2a044b93820402db845b0bff30c7a2d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2a044b93820402db845b0bff30c7a2d
record_format	dspace
spelling	oai:doaj.org-article:a2a044b93820402db845b0bff30c7a2d2021-12-02T07:09:12ZTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis1177-5491https://doaj.org/article/a2a044b93820402db845b0bff30c7a2d2016-09-01T00:00:00Zhttps://www.dovepress.com/therapeutic-efficacy-of-monthly-subcutaneous-injection-of-daclizumab-i-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Stanley Cohan1,2,3 1Providence Multiple Sclerosis Center, 2Providence Brain and Spine Institute, 3Providence Health & Services, Portland, OR, USA Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable benefit–risk profile and attributes that encourage a high level of treatment adherence. Daclizumab is a humanized monoclonal antibody directed against CD25, the α subunit of the high-affinity interleukin 2 (IL-2) receptor, that reversibly modulates IL-2 signaling. Daclizumab treatment leads to antagonism of proinflammatory, activated T lymphocyte function and expansion of immunoregulatory CD56bright natural killer cells, and has the potential to, at least in part, rectify the imbalance between immune tolerance and autoimmunity in relapsing MS. The clinical pharmacology, efficacy, and safety of subcutaneous daclizumab have been evaluated extensively in a large clinical study program. In pivotal studies, daclizumab demonstrated superior efficacy in reducing clinical and radiologic measures of MS disease activity compared with placebo or intramuscular interferon beta-1a, a standard-of-care therapy for relapsing MS. The risk of hepatic disorders, cutaneous events, and infections was modestly increased. The monthly subcutaneous self-injection dosing regimen of daclizumab may be advantageous in maintaining patient adherence to treatment, which is important for optimal outcomes with MS disease-modifying therapy. Daclizumab has been approved in the US and in the European Union and represents an effective new treatment option for patients with relapsing forms of MS, and is currently under review by other regulatory agencies. Keywords: daclizumab, disease-modifying therapy, humanized monoclonal antibody, relapsing multiple sclerosis, therapeutic useCohan SDove Medical Pressarticledaclizumab high-yield processdisease-modifying therapyhumanized monoclonal antibodyrelapsing multiple sclerosistherapeutic useMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 10, Pp 119-138 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	daclizumab high-yield process disease-modifying therapy humanized monoclonal antibody relapsing multiple sclerosis therapeutic use Medicine (General) R5-920
spellingShingle	daclizumab high-yield process disease-modifying therapy humanized monoclonal antibody relapsing multiple sclerosis therapeutic use Medicine (General) R5-920 Cohan S Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
description	Stanley Cohan1,2,3 1Providence Multiple Sclerosis Center, 2Providence Brain and Spine Institute, 3Providence Health & Services, Portland, OR, USA Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable benefit–risk profile and attributes that encourage a high level of treatment adherence. Daclizumab is a humanized monoclonal antibody directed against CD25, the α subunit of the high-affinity interleukin 2 (IL-2) receptor, that reversibly modulates IL-2 signaling. Daclizumab treatment leads to antagonism of proinflammatory, activated T lymphocyte function and expansion of immunoregulatory CD56bright natural killer cells, and has the potential to, at least in part, rectify the imbalance between immune tolerance and autoimmunity in relapsing MS. The clinical pharmacology, efficacy, and safety of subcutaneous daclizumab have been evaluated extensively in a large clinical study program. In pivotal studies, daclizumab demonstrated superior efficacy in reducing clinical and radiologic measures of MS disease activity compared with placebo or intramuscular interferon beta-1a, a standard-of-care therapy for relapsing MS. The risk of hepatic disorders, cutaneous events, and infections was modestly increased. The monthly subcutaneous self-injection dosing regimen of daclizumab may be advantageous in maintaining patient adherence to treatment, which is important for optimal outcomes with MS disease-modifying therapy. Daclizumab has been approved in the US and in the European Union and represents an effective new treatment option for patients with relapsing forms of MS, and is currently under review by other regulatory agencies. Keywords: daclizumab, disease-modifying therapy, humanized monoclonal antibody, relapsing multiple sclerosis, therapeutic use
format	article
author	Cohan S
author_facet	Cohan S
author_sort	Cohan S
title	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
title_short	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
title_full	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
title_fullStr	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
title_full_unstemmed	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
title_sort	therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/a2a044b93820402db845b0bff30c7a2d
work_keys_str_mv	AT cohans therapeuticefficacyofmonthlysubcutaneousinjectionofdaclizumabinrelapsingmultiplesclerosis
_version_	1718399592891940864

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis

Ejemplares similares